Motus GI Holdings, Inc. (MOTS) Reports Q4 Loss, Lags Revenue Estimates
- Motus GI Holdings, Inc. (MOTS) delivered earnings and revenue surprises of 36.80% and 72.75%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- 03/31/2023
|
Motus GI Holdings, Inc. (MOTS) Reports Q3 Loss, Misses Revenue Estimates
- Motus GI Holdings, Inc. (MOTS) delivered earnings and revenue surprises of 9.63% and 14.72%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
- 11/14/2022
|
Motus GI Holdings, Inc. (MOTS) Q3 2022 Earnings Call Transcript
- Motus GI Holdings, Inc. (NASDAQ:MOTS ) Q3 2022 Earnings Conference Call November 14, 2022 4:30 PM ET Company Participants Garth Russell - Managing Director-LifeSci Advisors, LLC Tim Moran - Chief Executive Officer Andrew Taylor - Chief Financial Officer Mark Pomeranz - President & Chief Operating Officer Conference Call Participants Steve Lichtman - Oppenheimer and Co. Ben Haynor - Alliance Global Partners Operator Ladies and gentlemen, thank you for standing by, and welcome to the Motus GI Holdings, Inc. Third Quarter 2022 Financial and Operational Update. At this time, all participants are in a listen-only mode.
- 11/14/2022
|
Motus GI to Release Third Quarter Results and Provide a Business Update on November 14
- FORT LAUDERDALE, Fla., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, announced today that the Company will release its third quarter financial results on Monday, November 14, 2022, after the market close. Management will host a conference call and webcast at 4:30 p.m. ET to discuss the results and provide updates on recent corporate developments.
- 10/31/2022
|
Make Money With Penny Stocks in November? 3 Methods to Use
- Use these tips for profiting with penny stocks The post Make Money With Penny Stocks in November? 3 Methods to Use appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 10/25/2022
|
3 Penny Stock Predictions for 2023
- Penny stocks are companies that generally trade under $5 per share or have very low trading volume. They are also companies many investors ignore.
- 10/21/2022
|
Why Is Motus GI (MOTS) Stock Up 50% Today?
- Source: ArtemisDiana/Shutterstock In yet another topsy-turvy session in the markets, investors may want to look for bright spots in this uncertain time. One of today's biggest winners is Motus GI (NASDAQ: MOTS ), a maker of colonoscopy-related medical devices and technologies.
- 10/06/2022
|
Motus GI Holdings, Inc. (MOTS) Upgraded to Buy: What Does It Mean for the Stock?
- Motus GI Holdings, Inc. (MOTS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- 10/06/2022
|
Top Penny Stocks To Buy Now? 5 To Watch Under $5 Today
- 5 top penny stocks to buy for under $5 but are they worth the risk? The post Top Penny Stocks To Buy Now?
- 10/06/2022
|
Motus GI Holdings, Inc. (MOTS) CEO Tim Moran on Q2 2022 Results - Earnings Call Transcript
- Motus GI Holdings, Inc. (NASDAQ:MOTS ) Q2 2022 Earnings Conference Call August 11, 2022 4:30 PM ET Company Participants Garth Russell - Managing Director-LifeSci Advisors, LLC Tim Moran - Chief Executive Officer Andrew Taylor - Chief Financial Officer Mark Pomeranz - President and Chief Operating Officer Conference Call Participants Steven Lichtman - Oppenheimer Benjamin Haynor - Alliance Global Partners Boobalan Pachaiyappan - H.C. Wainwright Operator Ladies and gentlemen, thank you for standing by and welcome to the Motus GI Holdings, Inc. Second Quarter 2022 Financial and Operational Update.
- 08/11/2022
|
Motus GI to Release Second Quarter Results and Provide a Business Update on August 11
- FORT LAUDERDALE, Fla., July 21, 2022 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, announced today that the Company will release its second quarter financial results on Thursday, August 11, 2022, after the market close. Management will host a conference call and webcast at 4:30 p.m. ET to discuss the results and provide updates on recent corporate developments.
- 07/21/2022
|
Motus GI Holdings, Inc. (MOTS) CEO Tim Moran on Q1 2022 Results - Earnings Call Transcript
- Motus GI Holdings, Inc. (NASDAQ:MOTS ) Q1 2022 Earnings Conference Call May 12, 2022 4:30 PM ET Company Participants Garth Russell - Managing Director-LifeSci Advisors, LLC Tim Moran - Chief Executive Officer Andrew Taylor - Chief Financial Officer Mark Pomeranz - President and Chief Operating Officer Conference Call Participants Steven Lichtman - Oppenheimer Boobalan Pachaiyappan - H.C. Wainwright Operator Good day, and welcome to the Motus GI First Quarter 2022 Earnings Call.
- 05/12/2022
|
Will Motus GI Holdings, Inc. (MOTS) Report Negative Earnings Next Week? What You Should Know
- Motus GI Holdings, Inc. (MOTS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 05/05/2022
|
Motus GI to Release First Quarter Results and Provide a Business Update on May 12
- FORT LAUDERDALE, Fla., April 28, 2022 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, announced today that the Company will release its first quarter financial results on Thursday, May 12, 2022, after the market close. Management will host a conference call and webcast at 4:30 p.m. ET to discuss the results and provide updates on recent corporate developments.
- 04/28/2022
|
Motus GI Holdings, Inc. (MOTS) CEO Tim Moran on Q4 2021 Results - Earnings Call Transcript
- Motus GI Holdings, Inc. (MOTS) CEO Tim Moran on Q4 2021 Results - Earnings Call Transcript
- 03/29/2022
|
Motus GI Holdings, Inc. (MOTS) Reports Q4 Loss, Misses Revenue Estimates
- Motus GI Holdings, Inc. (MOTS) delivered earnings and revenue surprises of 0% and 27.21%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
- 03/29/2022
|
Motus GI to Release Fourth Quarter and Full Year 2021 Results and Provide a Business Update on March 29
- FORT LAUDERDALE, Fla., March 15, 2022 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, announced today that the Company will release its fourth quarter and full year financial results on Tuesday, March 29, 2022, after the market close. Management will host a conference call and webcast at 4:30 p.m. ET to discuss the results and provide updates on recent corporate developments.
- 03/15/2022
|
Motus GI to Participate in Two Upcoming Investor Conferences in March 2022
- FORT LAUDERDALE, Fla., March 02, 2022 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) (“Motus GI” or the “Company”), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, announced today that its management team is scheduled to participate in two upcoming investor conferences in March 2022.
- 03/02/2022
|
Trading Penny Stocks? Top Stock Market News for February 14th, 2022
- Check these penny stocks out for your watchlist today The post Trading Penny Stocks? Top Stock Market News for February 14th, 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 02/14/2022
|
Motus GI Holdings' (MOTS) CEO Tim Moran on Q3 2021 Results - Earnings Call Transcript
- Motus GI Holdings' (MOTS) CEO Tim Moran on Q3 2021 Results - Earnings Call Transcript
- 11/12/2021
|
Motus GI Hldgs Earnings Preview
- Motus GI Hldgs (NASDAQ:MOTS) is set to give its latest quarterly earnings report on Friday, 2021-11-12. Here's what investors need to know before the announcement.
- 11/11/2021
|
Motus GI Holdings, Inc. (MOTS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
- Motus GI Holdings, Inc. (MOTS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 11/05/2021
|
Motus GI Announces Enrollment of Patients at Second Site in the European Union Outpatient Study of the Pure-Vu® System
- FORT LAUDERDALE, Fla., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, today announced that GastroZentrum Lippe, one of the top private endoscopy clinics in Germany, has enrolled patients into the European Union (EU) outpatient study of the Pure-Vu System, which is evaluating the clinical outcomes in patients with a history of poor bowel preparation using a low volume preparation with limited diet restrictions and the Pure-Vu System. The study was initiated in mid-June 2021 with patients at the Radboud University Medical Center (Netherlands).
- 09/08/2021
|
Motus GI Holdings' (MOTS) CEO Tim Moran on Q2 2021 Results - Earnings Call Transcript
- Motus GI Holdings' (MOTS) CEO Tim Moran on Q2 2021 Results - Earnings Call Transcript
- 08/13/2021
|
Motus GI Holdings, Inc. (MOTS) Reports Q2 Loss, Tops Revenue Estimates
- Motus GI Holdings, Inc. (MOTS) delivered earnings and revenue surprises of 9.09% and 20.48%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
- 08/12/2021
|
Motus GI to Release Second Quarter Results and Provide a Business Update on August 12
- FORT LAUDERDALE, Fla., July 29, 2021 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, announced today that the Company will release its second quarter financial results on Thursday, August 12, 2021, after the market close. Management will host a conference call and webcast at 4:30 p.m. ET to discuss the results and provide updates on recent corporate developments.
- 07/29/2021
|
Motus GI to Present at the Ladenburg Thalmann Healthcare Conference
- FORT LAUDERDALE, Fla., June 29, 2021 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) (“Motus GI” or the “Company”), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, announced today that its management team is scheduled to present at the upcoming Ladenburg Thalmann Healthcare Conference begin held from July 13 to July 14.
- 06/29/2021
|
Motus GI Appoints Experienced Financial Biotech Executive, Sonja Nelson, to its Board of Directors and as Chair of Audit Committee
- FORT LAUDERDALE, Fla., June 23, 2021 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc. , (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, announced the appointment of Sonja Nelson, CPA to the Company's Board of Directors and as Chair of the Audit Committee. Ms. Nelson brings more than 25 years of financial and operational leadership and expertise in biotechnology, diagnostics, and biopharmaceuticals markets, including playing an integral role in the successful merger between NantKwest, Inc. (Nasdaq: NK) and Immunity Bio, Inc. (Nasdaq: IBRX).
- 06/23/2021
|
Motus GI's Pure-Vu System® Adopted by Sinai Hospital of Baltimore
- Implementation of the Pure-Vu System is designed to improve efficiencies and outcomes of GI endoscopy procedures Implementation of the Pure-Vu System is designed to improve efficiencies and outcomes of GI endoscopy procedures
- 05/25/2021
|
7 Cheap Stocks to Buy Now Under $3
- It can be difficult to find cheap stocks worth buying. But these seven companies look promising and are all under $3.
- 05/17/2021
|
Motus GI Holdings, Inc (MOTS) CEO Tim Moran on Q1 2021 Results - Earnings Call Transcript
- Motus GI Holdings, Inc (MOTS) CEO Tim Moran on Q1 2021 Results - Earnings Call Transcript
- 05/13/2021
|
Motus GI Holdings, Inc. (MOTS) Reports Q1 Loss, Tops Revenue Estimates
- Motus GI Holdings, Inc. (MOTS) delivered earnings and revenue surprises of -10.00% and 27.50%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
- 05/13/2021
|
Recap: Motus GI Hldgs Q1 Earnings
- Shares of Motus GI Hldgs (NASDAQ:MOTS) fell in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share increased 52.17% year over year to ($0.11), which missed the estimate of ($0.10).
- 05/13/2021
|
Motus GI Announces Publication of a Pure-Vu System® Cost Effectiveness Analysis in the Journal of Cost Effectiveness and Resource Allocation
- - - - - The article states Pure-Vu System is estimated to provide lifetime saving of $833- $992 per patient when compared to standard of care for outpatient colorectal cancer (CRC) screening and surveillance colonoscopy - - - - The researchers indicated that approximately 25% of 15 million outpatient colonoscopies performed annually in the US, or 3.75 million are inadequately prepped - - - - The article indicates that quality of life may be improved with the Pure-Vu System due primarily to a potential lower incidence of Colorectal Cancers as a result of early detection.
- 05/07/2021
|
MOTS Stock: The Big FDA News That Has Motus GI Holdings Soaring Today
- Motus GI Holdings (MOTS) stock is on the rise Friday following clearance from the FDA for one of the company's medical devices. The post MOTS Stock: The Big FDA News That Has Motus GI Holdings Soaring Today appeared first on InvestorPlace.
- 04/30/2021
|
Penny Stocks to Buy? Check These Tech Stocks Out
- Tech penny stocks are back in focus; check these 3 out The post Penny Stocks to Buy? Check These Tech Stocks Out appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 04/30/2021
|
MOTS Stock: From $1.09 To Over $1.60 Pre-Market Explanation
- The stock price of Motus GI Holdings Inc (NASDAQ: MOTS) increased by over 45% pre-market. This is why it happened.
- 04/30/2021
|
Motus GI Receives FDA Clearance to Market the Pure-Vu® System for Upper GI Endoscopy
- FORT LAUDERDALE, Fla., April 30, 2021 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (“FDA”) for a version of the Pure-Vu® System that is compatible with gastroscopes used during upper gastrointestinal (GI) endoscopy procedures to remove blood, blood clots and debris in order to provide a clear field-of-view for the endoscopist. This proprietary technology is the latest innovation for the Pure-Vu System platform that is specifically designed to integrate with therapeutic gastroscopes to enable safe and rapid cleansing during the procedure, while preserving established procedural workflow and techniques.
- 04/30/2021
|
Motus GI Stock Price Increased Over 2% Pre-Market: Why It Happened
- The stock price of Motus GI Holdings (NASDAQ: MOTS) increased by over 2% pre-market. This is why it happened.
- 04/06/2021
|
Motus GI Holdings, Inc. (MOTS) CEO Tim Moran on Q4 2020 Results - Earnings Call Transcript
- Motus GI Holdings, Inc. (MOTS) CEO Tim Moran on Q4 2020 Results - Earnings Call Transcript
- 03/16/2021
|
Motus GI Reports Fourth Quarter 2020 Financial Results and Provides Corporate Update
- FORT LAUDERDALE, Fla., March 16, 2021 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, today reported its financial results for the fourth quarter ended December 31, 2020, and provided a corporate update.
- 03/16/2021
|
Motus GI Announces First Patient Enrolled in a Pilot Study Using the Pure-Vu® System for Patients with Lower GI Bleeding Being Conducted by a Leading U.S. Medical Center
- FORT LAUDERDALE, Fla., March 15, 2021 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, announced today the enrollment of the first patient in a pilot study of the Pure-Vu® System. The study is evaluating the clinical and economic outcomes using the Pure-Vu System in patients with emergent lower gastrointestinal bleeding that are evaluated and treated in the Intensive Care Unit (ICU) or the rapid inpatient endoscopy suite.
- 03/15/2021
|
Motus GI to Participate in Two Upcoming Investor Conferences in March 2021
- FORT LAUDERDALE, Fla., March 01, 2021 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) (“Motus GI” or the “Company”), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, announced today that its management team is scheduled to participate at the two upcoming virtual investor conferences in March 2021.
- 03/01/2021
|
Motus GI Announces Warrant Exercise Agreement Resulting in Expected Gross Proceeds to the Company of up to $11 Million
- FORT LAUDERDALE, Fla., Jan. 27, 2021 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) (“Motus GI” or the “Company”), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, announced today that it has signed a warrant exercise agreement with an existing institutional investor that is expected to provide the Company with gross proceeds of up to $11.0 million.
- 01/27/2021
|
Motus GI Announces European Clearance of Enhanced Pure-Vu® GEN2 System to Harmonize with U.S. Configuration
- Regulatory approval for enhanced system is a key milestone that supports evaluation of strategic partnership opportunities in the EU - - - U.S. commercial rollout of Pure-Vu® GEN2 System enhancements initiated in Q4 2020
- 01/15/2021
|
Motus GI Expands Intellectual Property Portfolio with U.S. Patent for the Pure-Vu® System's Universal Method to Mount on the End of Most Commercial Colonoscopes
- Receives additional EU Patent for the Pure-Vu® System that protects the design of its fecal waste evacuation channels Receives additional EU Patent for the Pure-Vu® System that protects the design of its fecal waste evacuation channels
- 01/11/2021
|
Motus GI Scheduled to Participate in the Piper Sandler 32nd Annual Healthcare Conference
- FORT LAUDERDALE, Fla., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, announced today that its management team is scheduled to participate in the Piper Sandler 32nd Annual Healthcare Conference, which is scheduled to take place virtually from December 1-3, 2020.
- 11/25/2020
|
Motus GI Holdings, Inc.'s (MOTS) CEO Tim Moran on Q3 2020 Results - Earnings Call Transcript
- Motus GI Holdings, Inc.'s (MOTS) CEO Tim Moran on Q3 2020 Results - Earnings Call Transcript
- 11/12/2020
|
Motus GI Reports Third Quarter 2020 Financial Results and Provides Corporate Update
- FORT LAUDERDALE, Fla., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, today reported its financial results for the third quarter ended September 30, 2020, and provided a corporate update.
- 11/12/2020
|
Motus GI and NYU Langone Health Partner to Improve its Inpatient Colonoscopy Management
- FORT LAUDERDALE, Fla., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc. , (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions to help improve clinical outcomes, is launching a new clinical protocol with NYU Langone Health to incorporate the Company's Pure-Vu® GEN2 System (Pure-Vu) with the intention to improve the management of its inpatient colonoscopies.
- 11/03/2020
|
Motus GI to Release Third Quarter 2020 Results and Provide a Business Update on November 12
- FORT LAUDERDALE, Fla., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, announced today that the Company will release its third quarter 2020 financial results on Thursday, November 12, 2020, after the market close. Management will host a conference call and webcast at 4:30 p.m. ET to discuss the results and provide updates on recent corporate developments.
- 10/29/2020
|
Motus GI Holdings, Inc. (MOTS) Reports Q2 Loss, Lags Revenue Estimates
- Motus GI Holdings, Inc. (MOTS) delivered earnings and revenue surprises of 28.57% and -95.00%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
- 08/11/2020
|
Recap: Motus GI Hldgs Q2 Earnings
- Shares of Motus GI Hldgs (NASDAQ: MOTS) were flat after the company reported Q2 results. Quarterly Results Earnings per share increased 42.31% year over year to ($0.15), which beat the estimate of ($0.21). Revenue ofShares of Motus GI Hldgs (NASDAQ:MOTS) decreased 4.8% after the company reported Q2 results.Quarterly Results Earnings per share increased 42.31% year over year to ($0.15), which beat the estimate of ($0.21).Revenue of $1,000 decreased by 75.00% from the same period last year, which missed the estimate of $20,000.Outlook Motus GI Hldgs hasn't issued any earnings guidance for the time being.Motus GI Hldgs hasn't issued any revenue guidance for the time being.Conference Call Details Date: Aug 11, 2020View more earnings on MOTSTime: 04:30 PMET Webcast URL: http://public.viavid.com/player/index.php?id=140402Recent Stock Performance 52-week high: $2.9952-week low: $0.46Price action over last quarter: Up 12.26%Company Description Motus GI Holdings Inc is a medical technology company dedicated to improving endoscopy outcomes, lowering costs and enhancing patient experiences. The company is focused on the development and commercialization of the Pure-Vu System to improve the colonoscopy experience and assist in the early detection and prevention of colorectal cancer and other diseases of the rectum and colon.See more from Benzinga * Earnings Scheduled For August 11, 2020(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- 08/11/2020
|
Motus GI Reports Second Quarter 2020 Financial Results and Provides Corporate Update
- * The Pure-Vu® System launched in more than 20 major U.S. hospitals, with new evaluations added during the quarter * The Pure-Vu® System has demonstrated the ability to improve first-time, on-time colonoscopy procedures to optimize hospital efficiencies during COVID-19 * Digitized go-to-market model improved customer support and engagementFORT LAUDERDALE, Fla., Aug. 11, 2020 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, today reported its financial results for the second quarter ended June 30, 2020, and provided a corporate update.“The impact of the pandemic has amplified the importance of hospital efficiency, and Pure-Vu® can play a key role in ensuring colonoscopy procedures are completed on time, the first time, which can result in clear clinical outcomes and positive economic benefits. Despite the difficult market conditions associated with Covid-19, I am pleased that we continue to make solid progress, gain new evaluations at top GI hospitals, and are seeing many of them progress through the VAC process towards purchase and utilization. We remain committed to executing phase one of our strategy toward building a strong group of prominent institutions and key opinion leaders that are advocates for Pure-Vu®’s role in the GI suite,” stated Tim Moran, Chief Executive Officer of Motus GI. “Our decisive effort to digitize our go-to-market model is yielding positive results as many hospitals continue to restrict sales representative access due to COVID-19,” Mr. Moran continued. “We are pleased with the early adoption of The Pure-Vu® app that was launched late-May. This app provides a wide range of valuable resources for Pure-Vu® System users. As we monitor uptake of the app by facility, it is clear to us that this approach is being embraced by both physicians and staff. These new tools allow us to have direct touchpoints with physicians and be well aligned as they continue to ramp procedural volumes back toward normal levels,” concluded Mr. Moran.Progress UpdatesSince the first commercial placement of a Pure-Vu® System in October 2019, Motus GI has focused its U.S. sales efforts on early adopter hospitals and larger hospital networks that conduct anywhere from 500 to more than 1,000 inpatient colonoscopy procedures per year. During this time, Motus GI has placed the Pure-Vu® System in more than 20 of these targeted hospitals. In the second quarter, the Company initiated new Pure-Vu evaluations at UC-Irvine Health, Sinai Hospital Baltimore, Memorial Hermann and Geisinger Medical Center. Even in the early evaluation stage, these hospitals are seeing the benefits of Pure-Vu® as exemplified by UC-Irvine who is now working towards implementing a 24-hour or less patient bowel preparation protocol using Pure-Vu® with the objective of avoiding unnecessary extended hospitalizations. The Company believes this type of protocol has the potential to be adopted more widely over time as it can provide improvement in both patient care and hospital economics. Dr. Jason Samarasena, a key interventional gastroenterologist at UCI, shared the following thoughts based on his experience to date, "Pure-Vu® has been instrumental in addressing the clinical needs of our colonoscopy patients that present in the GI Lab with inadequate bowel prep. Inadequately prepped patients are a problem that we see regularly, and before the Pure-Vu® System’s availability, these patient's procedures were either delayed or even aborted prior to completion, leading to unnecessary additional nights of hospitalization. Pure-Vu® has allowed us to diagnose these patients earlier, which enables us to therapeutically treat when appropriate. Especially in light of Covid-19, we strive to avoid extended hospitalizations due to insufficient bowel prep and with Pure-Vu® we believe we can get a high-quality exam in less than 24 hours on most patients. This has a significant impact not only on overall patient care but also hospital economics." In addition, existing customers began performing Pure-Vu supported procedures again, although at a slower pace. The Company is in the process of gathering hospital case studies from the prominent hospitals currently using the Pure-Vu® System in order to provide broader industry awareness of the Pure-Vu® System and the real-world benefits it can provide in terms of clinical and economic outcomes. In addition, Motus GI has engaged a robust pipeline of approximately 150 target hospitals and continues to develop a growing schedule of product evaluations at key hospital systems.In the second quarter of 2020, the Company received notice that the U.S. Patent and Trademark Office (USPTO) issued patent No. 10646108, which provides additional protection for the Company’s flagship product – the Pure-Vu® System. The patent covers Motus GI’s proprietary sensing technology and enhanced suction control systems increasing integrated interactions with other colonoscope technology. The Company has now more than 25 granted patents and 25 pending patents protecting the Pure-Vu® System.COVID-19 Pandemic ImpactIn the second quarter of 2020, Motus GI’s business was most directly impacted by two main market themes: 1) a dramatic reduction in overall colonoscopy procedural volume as hospitals turned their attention to addressing COVID-19 related patients and, when possible, either cancelled or delayed colonoscopies unless absolutely necessary; and 2) hospital COVID-19 safety protocols preventing Motus GI sales representatives from entering most hospital accounts, which limited their ability to drive new system placements and utilization of systems already placed. Overall, Motus GI recognizes that the challenges of COVID-19 due to social distancing recommendations and other safety precautions will impact its ability to begin new scheduled evaluations of the Pure-Vu® System in the sales pipeline. The Motus GI management team continues to closely monitor the impact of the COVID-19 pandemic across the U.S. to assess its impact on the Company’s business.In a further effort to adjust to the current operating environment, the Company has taken a proactive approach to provide support to the hospitals currently using the Pure-Vu® System. The sales team has maintained continuous contact with customers and is now offering remote support for the Pure-Vu® System. This includes enabling the team to virtually conduct in-service assistance to physicians and their staff during procedures, which has already resulted in several Pure-Vu® enabled colonoscopies to be successfully supported remotely. As part of this effort, in late-May we launched a new mobile Motus GI APP that provides a plethora of valuable resources for Pure-Vu® System users. Specifically, this app provides chaptered and narrated video support that covers the set-up and use of the Pure-Vu® System. We are pleased with the early adoption of our app and have seen a growing number of downloads in just a couple of months. Motus GI also has built the appropriate inventory, of both workstations and disposable sleeves, to supply its customers continued use of the system for the next several months, and its manufacturing partners continue to be fully operational. Financial Results for the Quarter Ended June 30, 2020As announced just ahead of the beginning of the second quarter, on March 30, 2020, Motus GI implemented a cost reduction strategy that the Company believes will help it to navigate the market slowdown as a result of COVID-19, while continuing to advance its commercial and strategic objectives for the Pure-Vu® System. The Company has largely completed this effort and has reduced its quarterly cash burn by approximately 50% compared to previously forecasted rates as it enters the second half of 2020.For the three months ended June 30, 2020, the Company reported a net loss of approximately $4.4 million, or a net loss per diluted share of $0.15, compared to $5.7 million, or a net loss per diluted share of $0.26, for the same period last year. During the second quarter, net cash used in operating activities and for the purchase of fixed assets was $4.3 million as compared to a similar $4.3 million for the same period of 2019.In connection with the cost reduction strategy, the total one-time restructuring charges of $624 thousand, plus other related expenses, were at the low end of the initially projected range of $1.0 million to $1.5 million. We do not expect any further material costs associated with this program for the remainder of the year. The Company reported approximately $17.1 million in cash, cash equivalents and investments as of June 30, 2020, compared to $28.7 million as of December 31, 2019. The Company believes its cash, cash equivalents and investments will be sufficient to ensure compliance with the Silicon Valley Bank (SVB) liquidity covenant into late fourth quarter 2020 and meet its anticipated cash requirements into 2021.Conference Call:The Motus GI management team has scheduled a conference call for today at 4:30 p.m. ET to discuss these results. To access the conference call, investors are invited to dial (877) 407-0792 (U.S. and Canada) or (201) 689-8263 (International). The conference ID number is 13705843. A live audio webcast can be accessed by visiting the investor relations section of the Company’s website, www.motusgi.com or http://public.viavid.com/index.php?id=140402. A replay of the webcast will be archived on the Motus GI website for 90 days following the event.About Motus GIMotus GI Holdings, Inc. is a medical technology company, with subsidiaries in the U.S.
- 08/11/2020
|
Motus GI to Release Second Quarter 2020 Results and Provide a Business Update on August 11th
- FORT LAUDERDALE, Fla., July 21, 2020 -- Motus GI Holdings, Inc., (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that.
- 07/21/2020
|
Hedge Funds Have Never Been More Bullish On Motus GI Holdings, Inc. (MOTS)
- At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (see why hell is coming). In these volatile markets we scrutinize hedge fund filings to get a reading on which direction each stock might be going. […]
- 07/06/2020
|
Analyzing Motus GI (NASDAQ:MOTS) & Sensus Healthcare (NASDAQ:SRTS)
- Sensus Healthcare (NASDAQ:SRTS) and Motus GI (NASDAQ:MOTS) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, valuation, profitability, analyst recommendations, risk, dividends and earnings. Analyst Ratings This is a summary of current ratings for Sensus Healthcare and Motus GI, […]
- 07/03/2020
|
Cold-blooded killer of 16-year-old Kearny girl won’t get new trial
- An appellate court panel has denied a bid for a new trial by a Pennsylvania man who executed a defenseless 16-year-old Kearny girl to send a message during a family dispute.
- 06/18/2020
|
Analysts Are Bullish on These Healthcare Stocks: Momenta Pharma (MNTA), Otonomy (OTIC) - Markets
- There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Momenta Pharma
- 06/16/2020
|
Motus GI Launches Mobile App to Provide On-Demand Support and Resources to Hospitals Using the Pure-Vu® System
- This new mobile solution is a part of a larger effort to diversify and digitize much of the go-to-market content for the Pure-Vu System, which is being adopted by a growing number of major U.S. hospitals since being commercially launched at the end of 2019. This new mobile interface provides Pure-Vu System users instant access to on-demand video support and training resources, including demo and intra-procedural videos, live set-up tutorials, and case studies.
- 06/15/2020
|
Motus GI to Present at the Virtual Investor Fireside Chat Series
- FORT LAUDERDALE, Fla., June 11, 2020 -- Motus GI Holdings, Inc., (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that.
- 06/11/2020
|
Working from home? You might be able to expense a new desk
- As the share of remote workers explodes amid the coronavirus pandemic, more companies are offering to cover their staff's home-office expenses.
- 06/03/2020
|
Some Motus GI Holdings, Inc. (NASDAQ:MOTS) Analysts Just Made A Major Cut To Next Year's Estimates
- One thing we could say about the analysts on Motus GI Holdings, Inc. (NASDAQ:MOTS) - they aren't optimistic, having...
- 05/20/2020
|
Motus GI Holdings, Inc. (NASDAQ:MOTS) Analysts Are Cutting Their Estimates: Here's What You Need To Know
- It's shaping up to be a tough period for Motus GI Holdings, Inc. (NASDAQ:MOTS), which a week ago released some...
- 05/17/2020
|
Motus GI Holdings, Inc. (MOTS) Reports Q1 Loss, Misses Revenue Estimates
- Motus GI Holdings, Inc. (MOTS) delivered earnings and revenue surprises of -4.55% and -81.33%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
- 05/14/2020
|
Motus GI Reports First Quarter 2020 Financial Results and Provides Corporate Update
- The Pure-Vu® System approved and placed in 19 major U.S. hospitals since Q4 2019 launchMore than 75 GI physicians trained on the new Pure-Vu® System technologyKey regulatory.
- 05/14/2020
|
What's in the Cards for SmileDirectClub's (SDC) Q1 Earnings?
- Stocks Analysis by Zacks Investment Research covering: CVS Health Corp, BioLife Solutions Inc, Hexo Corp, SmileDirectClub Inc. Read Zacks Investment Research's latest article on Investing.com
- 05/12/2020
|
Motus GI Expands Intellectual Property Portfolio with U.S. Patent for the Pure-Vu® System’s Sensing Technology and Suction Control
- “This patent reinforces the continued protection of our Pure-Vu System designed to enable endoscopists to achieve clear visualization of the colon, which we believe may facilitate a quality colonoscopy upon first attempt,” said Tim Moran, chief executive officer of Motus GI. “We continue to grow our intellectual property portfolio, expanding our first mover advantage in the endoscopy space with an innovative platform that can be integrated with a variety of scopes to perform colonoscopies.”
- 05/05/2020
|
Motus GI to Release First Quarter 2020 Results and Provide a Business Update on May 14th
- FORT LAUDERDALE, Fla., May 04, 2020 -- Motus GI Holdings, Inc., (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that.
- 05/04/2020
|
3 Penny Stocks That Could Double Despite COVID-19 Woes
- How to make sense of the markets these days? Starting two months ago, we entered the steepest, fasted bear market slide in modern history – only to have stocks turn around for a sustained rally that has lasted over 4 weeks now. The volatility comes from the economic impact of the various ‘social distancing
- 04/23/2020
|
Analysts Offer Insights on Healthcare Companies: Rockwell Med (RMTI) and Motus Gi Holdings (MOTS)
- There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Rockwell Med (RMTI) and Motus Gi Holdings (MOTS) with
- 04/21/2020
|
Analysts Offer Insights on Healthcare Companies: Rockwell Med (NASDAQ: RMTI) and Motus Gi Holdings (NASDAQ: MOTS)
- There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Rockwell Med (
RMTI
–
Research Report
) and Motus Gi Holdings (
MOTS
–
Research Report
) with bullish sentiments.
Rockwell Med (RMTI)
H.C. Wainwright analy
- 04/21/2020
|
Inspire Medical Systems (NYSE:INSP) versus Motus GI (NYSE:MOTS) Head to Head Review
- Inspire Medical Systems (NYSE:INSP) and Motus GI (NASDAQ:MOTS) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, valuation, institutional ownership, dividends and profitability. Profitability This table compares Inspire Medical Systems and Motus GI’s net margins, return on […]
- 04/12/2020
|
Critical Contrast: Motus GI (NASDAQ:MOTS) versus Teleflex (NASDAQ:TFX)
- Motus GI (NASDAQ:MOTS) and Teleflex (NYSE:TFX) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, profitability, analyst recommendations and earnings. Valuation and Earnings This table compares Motus GI and Teleflex’s revenue, earnings per share (EPS) and valuation. […]
- 04/12/2020
|
Motus GI Receives Approval from the Israeli Ministry of Health to Initiate Commercial Sales of its GEN2 Pure-Vu® System in Israel
- FORT LAUDERDALE, Fla., April 07, 2020 -- Motus GI Holdings, Inc., (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that.
- 04/07/2020
|
Analysts Are Bullish on These Healthcare Stocks: Motus Gi Holdings (MOTS), Cytokinetics (CYTK)
- There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Motus Gi Holdings (MOTS), Cytokinetics (CYTK) and Flowr
- 03/31/2020
|
Analysts Are Bullish on These Healthcare Stocks: Motus Gi Holdings (MOTS), Cytokinetics (CYTK)
- There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Motus Gi Holdings (
MOTS
–
Research Report
), Cytokinetics (
CYTK
–
Research Report
) and Flowr (
FLWPF
–
Research Report
) with bullish sentiments.
Motus
- 03/31/2020
|
Motus GI Reports Fourth Quarter and Year End 2019 Financial Results and Provides Corporate Update
- Commercial launch on track, including the Pure-Vu® System placed in more than 15 major U.S. hospitals since Q4 2019More than 50 GI physicians trained on the new Pure-Vu® System.
- 03/30/2020
|
Motus GI Holdings, Inc. to Host Earnings Call
- NEW YORK, NY / ACCESSWIRE / March 30, 2020 / Motus GI Holdings, Inc. (NASDAQ:MOTS) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 30, 2020 at 4:30 ...
- 03/30/2020
|
Motus GI Receives CE Mark Approval for GEN2 Pure-Vu System
- Motus GI Holdings, Inc., (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, today announced receiving CE (Conformité Européene) Mark approval for the GEN2 Pure-Vu System. The Company is assessing potential strategic partnership opportunities for the Pure-Vu System with established medical device companies and distributors with commercial operations across the EU.
- 03/27/2020
|
Fort Lauderdale medical technology company will relocate headquarters to Boston area
- Motus GI Holdings, a medical device company in Fort Lauderdale, will relocate its headquarters to Boston in the second quarter. The move is expected to improve operations as the medical technology company (Nasdaq: MOTS) grows sales for its endoscopy product, according to a Thursday announcement. “We are relocating Motus GI headquarters to the greater Boston area to foster closer collaboration between key functions, which will drive efficiency in our business operations,” CEO Tim Moran said.
- 03/12/2020
|
Motus GI Moving Corporate Headquarters to Greater Boston Area to Foster Closer Collaboration and Drive Operational Efficiency
- Motus GI Holdings, Inc., (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, today announced that it is relocating its corporate headquarters from Fort Lauderdale, Fl. to Boston in Q2 2020.
- 03/12/2020
|
Motus GI to Release Fourth Quarter 2019 Results and Provide a Business Update on March 30th
- Motus GI Holdings, Inc., (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, announced today that the Company will release its fourth quarter and year ended December 31, 2019 financial results on Monday, March 30, 2020, after the market close. Management will also host a conference call and webcast at 4:30 p.m. ET to discuss the results and provide updates on recent corporate developments.
- 03/04/2020
|
Investors Who Bought Motus GI Holdings (NASDAQ:MOTS) Shares A Year Ago Are Now Down 51%
- It is doubtless a positive to see that the Motus GI Holdings, Inc. (NASDAQ:MOTS) share price has gained some 47% in...
- 02/17/2020
|
Hedge Funds Have Never Been This Bullish On Motus GI Holdings, Inc. (MOTS)
- How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies. However, an easier way is to look at the stocks that smart money investors are collectively bullish on. Hedge funds and other institutional investors usually invest large amounts of […]
- 12/22/2019
|
Will Motus GI Continue to Surge Higher?
- As of late, it has definitely been a great time to be an investor in Motus GI Holdings.
- 12/13/2019
|
Motus GI Holdings, Inc. (MOTS) Reports Q3 Loss, Lags Revenue Estimates
- Motus GI Holdings, Inc. (MOTS) delivered earnings and revenue surprises of 28.00% and -97.00%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
- 11/14/2019
|
Motus GI Holdings (NASDAQ:MOTS) Will Have To Spend Its Cash Wisely
- There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
- 10/21/2019
|
